Dyadic International, Inc. (DYAI)
Nasdaq · Healthcare · Biotechnology
$0.454−0.39%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $18.2M
- 52-week range
- $0.34 – $1.60
- 52-week change
- −59.65%
- EPS (trailing)
- −$0.23
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Revenue
- $3.1M (−11.59%)
- Net income
- −$7.4M
- Operating margin
- −232.8%
- Diluted EPS
- −$0.23
From the company’s annual report on SEC EDGAR.
About Dyadic International, Inc.
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Headquarters: Jupiter, United States · 5 employees · dyadic.com